

Docket No. 58075-Z/JPW/GJG/JAS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Ridwan ShabsighSerial No. : 10/658,991 Examiner: R. M. KellyFiled : September 9, 2003 Group Art Unit: 1633For : USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE TREATMENT
OF ERECTILE DYSFUNCTIONMail Stop Amendment
COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450Date: September 11, 2007

Sir:

Transmitted herewith is an amendment to the above-identified application.

X Small entity status of this application under 37 C.F.R. §1.9 and §1.27 has been previously established.

 A verified statement to establish small entity status under 37 C.F.R. §1.9 and §1.27 is enclosed.

X No additional fee is required.

The filing fee is calculated as follows:

	Number after Amend-ment	Highest Number Previously Paid For ¹	Number of Extra Claims Presented	RATE			FEE	
				Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	12 -	* 20 =	*** 0 X	\$25	\$50	=	0	
Indepen- -dent Claims	3 -	** 3 =	*** 0 X	\$100	\$200	=	0	
Multiple Dependent Claim(s) Presented For First Time <u> </u> Yes <u>X</u> No				\$180	\$360	=	0	
				TOTAL ADDITIONAL FEE \$ 0				

¹ The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims originally filed.

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 20, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0".

Applicant(s): Ridwan Shabsigh
Serial No. : 10/658,991
Filed : September 9, 2003

Amendment Transmittal Letter
Page 2

The following are also enclosed:

☒ One additional copy of this Amendment Transmittal Letter
☒ Return Receipt Postcard
_____ An Information Disclosure Statement, including Form PTO-1449
(Copies of citations included: Yes _____ No _____
and a fee of \$ _____ included)
_____ A Petition for an Extension of Time, including a fee of
\$ _____ for a Petition for _____ Month(s) Extension of Time
_____ Other (identify): _____

THE TOTAL FEE DUE IS \$ 0.

☒ A check in the amount of \$ 0 is enclosed.
_____ Please charge Deposit Account No. _____ in the amount of
\$ _____.
☒ The Commissioner is hereby authorized to charge any additional fees
required or credit any overpayment to Deposit Account No. 03-3125
as follows:
☒ Fees under 37 C.F.R. §1.16 for the presentation of extra claims
_____ Patent application processing fees under 37 C.F.R. §1.17

Respectfully submitted,

I hereby certify that this
correspondence is being deposited this
date with the U.S. Postal Service with
sufficient postage as first class mail
in an envelope addressed to:
Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.
Gary J. Gershik 9/11/07
Date
Gary J. Gershik
Reg. No. 39,992

Gary J. Gershik
John P. White
Registration No. 28,678
Gary J. Gershik
Registration No. 39,992
Attorneys for Applicant(s)
Cooper & Dunham LLP (Customer #23432)
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400



Dkt. 58075-Z/JPW/GJG/JAS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Ridwan Shabsigh
U.S. Serial No.: 10/658,991 Examiner: Robert M. Kelly
Filing Date : September 9, 2003 Group Art Unit: 1633
For : USES OF VASCULAR ENDOTHELIAL GROWTH FACTOR
IN THE TREATMENT OF ERECTILE DYSFUNCTION

1185 Avenue of the Americas
New York, New York 10036
September 11, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

AMENDMENT IN RESPONSE TO JUNE 13, 2007 OFFICE ACTION

This Amendment is submitted in response to the June 13, 2007 Office Action issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the June 13, 2007 Office Action is due September 13, 2007. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

Amendments to the claims begin on page 3 of this paper.

Remarks begin on page 5 of this paper.